Rafferty Asset Management LLC Sells 12,582 Shares of Inhibrx, Inc. (NASDAQ:INBX)

Rafferty Asset Management LLC reduced its holdings in Inhibrx, Inc. (NASDAQ:INBXFree Report) by 10.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 103,246 shares of the company’s stock after selling 12,582 shares during the quarter. Rafferty Asset Management LLC owned about 0.22% of Inhibrx worth $3,923,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. RA Capital Management L.P. increased its stake in shares of Inhibrx by 22.6% in the 3rd quarter. RA Capital Management L.P. now owns 4,724,207 shares of the company’s stock valued at $86,689,000 after acquiring an additional 870,340 shares in the last quarter. Eventide Asset Management LLC bought a new position in shares of Inhibrx during the 3rd quarter worth about $7,964,000. Wellington Management Group LLP boosted its position in shares of Inhibrx by 24.4% during the 3rd quarter. Wellington Management Group LLP now owns 174,899 shares of the company’s stock worth $3,209,000 after purchasing an additional 34,310 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Inhibrx in the 4th quarter valued at about $894,000. Finally, Vanguard Group Inc. increased its position in Inhibrx by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,789,811 shares of the company’s stock valued at $32,843,000 after buying an additional 18,271 shares in the last quarter. 82.46% of the stock is owned by institutional investors and hedge funds.

Inhibrx Stock Up 2.5 %

Shares of NASDAQ:INBX opened at $16.65 on Friday. The company has a debt-to-equity ratio of 17.68, a quick ratio of 3.82 and a current ratio of 3.82. Inhibrx, Inc. has a 52-week low of $15.25 and a 52-week high of $18.95. The business’s 50 day simple moving average is $32.33 and its two-hundred day simple moving average is $32.96. The firm has a market cap of $872.49 million, a P/E ratio of -3.31 and a beta of 2.87.

Insider Transactions at Inhibrx

In other Inhibrx news, Director Jon Faiz Kayyem purchased 57,549 shares of Inhibrx stock in a transaction that occurred on Wednesday, June 5th. The stock was acquired at an average price of $17.32 per share, with a total value of $996,748.68. Following the transaction, the director now owns 1,150,410 shares in the company, valued at approximately $19,925,101.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Brendan P. Eckelman sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.30, for a total value of $10,290,000.00. Following the transaction, the insider now owns 1,735,553 shares in the company, valued at $59,529,467.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jon Faiz Kayyem bought 57,549 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were bought at an average cost of $17.32 per share, for a total transaction of $996,748.68. Following the transaction, the director now owns 1,150,410 shares of the company’s stock, valued at $19,925,101.20. The disclosure for this purchase can be found here. 22.20% of the stock is owned by insiders.

Inhibrx Profile

(Free Report)

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

Featured Articles

Want to see what other hedge funds are holding INBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inhibrx, Inc. (NASDAQ:INBXFree Report).

Institutional Ownership by Quarter for Inhibrx (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.